IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance
The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2006 by University of Turin, Italy.
Recruitment status was: Recruiting
Recruitment status was: Recruiting
Sponsor:
University of Turin, Italy
Information provided by:
University of Turin, Italy
ClinicalTrials.gov Identifier:
NCT00370617
First received: August 30, 2006
Last updated: November 13, 2006
Last verified: November 2006
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Chronic hepatitis C virus (HCV) infection is associated with an increased risk for the development of type 2 diabetes and HCV infection itself may promote insulin resistance, irrespective of the severity of liver disease.
Insulin resistance seems to be genotype specific and may play a role in fibrogenesis in chronic hepatitis C.
In an “in vitro” model, increased levels of insulin may promote increased HCV replication.
RATIONALE Decreased insulin resistance and reduced hyperinsulinemia may facilitate the efficacy of anti-viral drugs on HCV replication.
| Condition | Intervention | Phase |
|---|---|---|
| Chronic Hepatitis C Insulin Resistance | Drug: metformin | Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment |
| Official Title: | An Efficacy and Safety Study Comparing Pegylated-Interferon and Ribavirin Plus Metformin to Pegylated-Interferon and Ribavirin in the Treatment of naïve Patients With Genotype 1 Chronic HCV Infection and Insulin Resistance |
Resource links provided by NLM:
Further study details as provided by University of Turin, Italy:
Primary Outcome Measures:
- Combined end-point of non-detectable serum HCV-RNA (<100 copies/mL) and
- normal serum ALT activity at the end of the 24 week treatment-free follow up period
Secondary Outcome Measures:
- End-of-treatment virological and biochemical response
- Sustained virological and biochemical response
- End-of-treatment improvement of insulin resistance
- End-of-treatment improvement of liver histology
| Estimated Enrollment: | 200 |
| Study Start Date: | September 2006 |
| Estimated Study Completion Date: | January 2009 |
Chronic hepatitis C virus (HCV) infection is associated with an increased risk for the development of type 2 diabetes and HCV infection itself may promote insulin resistance, irrespective of the severity of liver disease.
- In patients with HCV infection, an increase in fasting insulin levels is associated with the presence of serum HCV core, the severity of hepatic fibrosis and a decrease in expression of insulin receptor substrate (IRS) 1 and IRS2, central molecules of the insulin-signaling cascade. Down-regulation of IRS1 and IRS2 has also been observed in HCV core-transgenic mice livers and HCV core-transfected human hepatoma cells.
- High levels of tumor necrosis factor-alpha, which acts by disturbing tyrosine phosphorylation of insulin receptor substrate-1, may be associated with insulin resistance both in animal models and in HCV patients.
Insulin resistance seems to be genotype specific and may play a role in fibrogenesis in chronic hepatitis C.
- In patients infected with genotype non-3, insulin resistance is associated with the degree of fibrosis, the rate of fibrosis progression and previous failed antiviral treatment.
- Insulin resistance, fibrosis, and genotype are independent predictors of the response to antiviral therapy in chronic hepatitis C patients treated with peginterferon plus ribavirin. A sustained virological response is achieved in 33% of patients with genotype 1 and insulin resistance compared with 60% of genotype 1 patients without insulin resistance.
- Insulin resistance is associated with a 3-fold risk of failure to antiviral treatment in patients with genotype 1 In an “in vitro” model, increased levels of insulin may promote increased HCV replication.
RATIONALE Decreased insulin resistance and reduced hyperinsulinemia may facilitate the efficacy of anti-viral drugs on HCV replication.
INDICATION Genotype 1 Chronic HCV hepatitis (CHC) associated with insulin resistance (IR).
OBJECTIVES To compare the efficacy and safety of Pegylated-Interferon and Ribavirin plus metformin to Pegylated-Interferon and Ribavirin for treatment of naïve patients with Genotype 1 Chronic HCV infection and insulin resistance.
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- No previous antiviral treatment
- Persistently elevated alanine aminotransferase (ALT) and quantifiable HCV-RNA (>2000 copies/ml)
- Liver biopsy (within 12 months) consistent with CHC with or without cirrhosis
- Compensated liver disease (Child-Pugh grade A)
- Insulin resistance (evaluated by HOMA-R and OGTT)
- Negative pregnancy test
Exclusion Criteria:
- Type 2 Diabetes (according to ADA criteria)
- BMI > 30
- Alcohol consumption > 30 g/day
- Other forms of liver disease (HBV, autoimmune, genetic), HIV infection.
- Anemia
- Psychiatric disease
- Thyroid disease poorly controlled
- Overt cirrhosis, hepatocellular carcinoma
- Significant cardiac, renal, pulmonary disease, seizures.
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00370617
Please refer to this study by its ClinicalTrials.gov identifier: NCT00370617
Contacts
| Contact: Mario Rizzetto, MD | +39-011-6336397 | mrizzetto@molinette.piemonte.it | |
| Contact: Elisabetta Bugianesi, MD | +39-011-6336397 | ebugianesi@yahoo.it |
Locations
| Italy | |
| Division of Gastroenterology, University of Torino, Ospedale San Giovanni Battista | Recruiting |
| Torino, Italy, 10126 | |
| Contact: Mario Rizzetto, MD +39-011-6336397 mrizzetto@molinette.piemonte.it | |
| Contact: Elisabetta Bugianesi, MD +39-011-6336397 ebugianesi@yahoo.it | |
| Sub-Investigator: Elisabetta Bugianesi, MD | |
Sponsors and Collaborators
University of Turin, Italy
Investigators
| Principal Investigator: | Mario Rizzetto, MD | University of Torino |
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00370617 History of Changes |
| Other Study ID Numbers: |
METVIRAL |
| Study First Received: | August 30, 2006 |
| Last Updated: | November 13, 2006 |
Keywords provided by University of Turin, Italy:
|
chronic hepatitis C insulin resistance therapy |
Additional relevant MeSH terms:
|
Hepatitis Hepatitis C Hepatitis, Chronic Insulin Resistance Hepatitis C, Chronic Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Virus Diseases Flaviviridae Infections RNA Virus Infections Hyperinsulinism Glucose Metabolism Disorders |
Metabolic Diseases Insulin Metformin Interferons Ribavirin Hypoglycemic Agents Physiological Effects of Drugs Antineoplastic Agents Antiviral Agents Anti-Infective Agents Antimetabolites Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on August 22, 2017